Turn Therapeutics (NASDAQ:TTRX) Upgraded by Wall Street Zen to “Hold” Rating

Turn Therapeutics (NASDAQ:TTRX) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

TTRX has been the topic of a number of other reports. D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a research note on Tuesday, March 24th. Weiss Ratings raised Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Turn Therapeutics presently has an average rating of “Hold” and a consensus price target of $8.00.

Turn Therapeutics Price Performance

Shares of TTRX opened at $9.12 on Friday. The business’s 50-day moving average is $6.34 and its 200-day moving average is $4.67. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.23 and a quick ratio of 2.23. The company has a market capitalization of $271.68 million and a price-to-earnings ratio of -48.00. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter.

Institutional Trading of Turn Therapeutics

Several large investors have recently added to or reduced their stakes in TTRX. Hodges Capital Management Inc. bought a new position in shares of Turn Therapeutics during the 4th quarter valued at $39,000. LPL Financial LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at $51,000. Tamar Securities LLC bought a new stake in Turn Therapeutics in the fourth quarter worth $59,000. Composition Wealth LLC bought a new stake in Turn Therapeutics in the fourth quarter worth $63,000. Finally, Jane Street Group LLC acquired a new position in Turn Therapeutics during the fourth quarter worth $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.